Intermittent cisplatin therapy for stage-III ovarian cancer patients following clinical remission

Intermittent cisplatin (CDDP) administration as consolidation therapy for s tage-III ovarian cancer was studied. No patients with residual disease at s urgery or at second-look operation or patients with <8 U/ml of CA125 after remission induction chemotherapy were enrolled in this study. Fifteen subje cts received intermittent chemotherapy, and 10 control patients did not. CD DP of 20 mg/m(2) for 5 days was administered every 3-4 months for 5 years. A significant increase in 5-year survival rate was found in the intermitten t chemotherapy group when compared with the control group. Side effects fro m the intermittent chemotherapy were controllable. Intermittent CDDP therap y seems to be an effective consolidation therapy for stage-ill ovarian canc er patients.